Drug
Modified-release Calcifediol Capsule clinical trials
- studies test it
- 8
- open now
- 1
- in phase 3
- 3
- first study started
- 2009
Keep track of what changes. Save the Modified-release Calcifediol Capsule studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Modified-release Calcifediol Capsule is read from its arms, and is right about nine times in ten.
Testing it · 8
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsRecruitingPhase 2OPKO Health, Inc.NCT07494045Written as CTAP101
- Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismTerminatedPhase 3OPKO Health, Inc.NCT05543928Written as CTAP101
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedPhase 3OPKO IP Holdings II, Inc.NCT01651000Written as CTAP101 30 μg capsules
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedPhase 3OPKO IP Holdings II, Inc.NCT01704079Written as CTAP101 30 μg capsules
- Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19CompletedPhase 2OPKO Health, Inc.NCT04551911Written as Rayaldee
- Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy SubjectsCompletedPhase 1OPKO Health, Inc.NCT03660800Written as CTAP101 Capsules
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic AcidCompletedPhase 1OPKO Health, Inc.NCT02274623Written as CTAP101 Capsules
- Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCompletedPhase 1OPKO IP Holdings II, Inc.NCT00888069Written as CTAP101 Capsules